|
Dr. Cusack joined Alseres Pharmaceuticals in July 2005 as Senior Vice President of Preclinical Development. Dr. Cusack brings over 30 years of chemistry and pharmacology management experience-from academe and the pharmaceutical industry-to ALSE. In 1994 Dr. Cusack was a founder of Aderis Pharmaceuticals and served as its Chief Scientific Officer, focusing on the research and development of dopamine- and purine-based technologies. Previously, he was Director of Pharmacology at Nelson Research and Whitby Research from 1988 to 1993. Before coming to the U.S., Dr. Cusack directed academic research in the U.K. from 1974 to 1988. His work on the chemistry and pharmacology of analogs of purine nucleosides and nucleotides was supported by the Medical Research Council at the Department of Pharmacology at the University of Cambridge and at Kings College London. Dr. Cusack graduated from the University of Auckland, N.Z. with a BSc and MSc in Chemistry, and was awarded his PhD in 1971 from the University of Bradford, U.K. with studies on the synthesis of nucleosides related to purines, pyrimidines, and imidazoles. Subsequently, he carried out post-doctoral research on the synthesis of oligonucleotides at the University Chemical Laboratory at Cambridge. Dr. Cusack has authored nearly 100 papers, articles, and book chapters and has presented at many international meetings in the U.S. and abroad. He maintains a faculty position as Adjunct Professor at the University of California, Irvine, where he taught medical school undergraduates the anti-infective therapeutic agents portions of their course requirements. Dr. Cusack serves on the curriculum committee of Pharmaceutical Education and Research Institute (PERI), where he has taught courses on the FDA and ICH non-clinical requirements for drug development, and he directs the pharmacology training courses for PERI. | 